News Releases Year: All News201920182017201620152014 Items per page All News2550 Summary ToggleContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Summary Toggle January 15, 2019 View News Release > Summary ToggleContraVir Pharmaceuticals to Present CRV431 Preclinical Data at the Anti-Fibrotic Drug Development Summit Summary Toggle November 27, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals to Present Two Posters at The Liver Meeting® 2018, Hosted by the American Association for the Study of Liver Diseases Summary Toggle November 6, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Completes Final Cohort Dosing in CRV431 Drug-Drug Interaction Study Summary Toggle October 30, 2018 View News Release > Summary ToggleRobert Foster Appointed Acting Chief Executive Officer of ContraVir Pharmaceuticals, Inc. Summary Toggle October 3, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces Completion of Phase 1 with CRV431 Summary Toggle September 18, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 Summary Toggle August 30, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Completes Data Analysis of Second Cohort in Part 1 of the Phase 1/2a Study of CRV431 Summary Toggle August 7, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Provides an Update to Corporate Objectives Summary Toggle August 6, 2018 View News Release > Summary ToggleContraVir Pharmaceuticals Reports Progress in Phase 1/2A Trial of CRV431 Summary Toggle July 23, 2018 View News Release > Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
